vTv Therapeutics (VTVT) Registration filing summary

Company overview and business model

• Focuses on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with lead candidate cadisegliatin (TTP399) in Phase 3 trials for type 1 diabetes as adjunctive insulin therapy.

• Cadisegliatin has FDA Breakthrough Therapy designation and is being evaluated for both type 1 and type 2 diabetes in ongoing and planned clinical trials.

• Resumed clinical development in 2025 after resolving an FDA clinical hold related to a Phase 1 study artifact.

Financial performance and metrics

• Raised approximately $51.0 million in February 2024 and $80.0 million in August 2025 through private placements, before deducting offering expenses.

• As of September 30, 2025, 3,938,018 shares of Class A common stock are outstanding.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders, except for cash proceeds from warrant exercises.

• Pre-Funded Warrants have an exercise price of $0.01 per share; Common Warrants have a weighted average exercise price of $22.98 per share.